OTC · Biotechnology

Bioasis Technologies Inc. (BIOAF) Stock

$0.00 OTC: BIOAF Healthcare

Bioasis Technologies Inc. is a developing biopharmaceutical enterprise dedicated to the discovery and advancement of treatments and diagnostic tools for various neurological conditions.

Valuation

MetricValue
Price$0.00
Market Cap$7941
P/E Ratio-0.12
P/B Ratio-0.19
P/S Ratio0.03
EPS (TTM)$-0.01
52-Week High$0.00
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE150.00%
ROA-80.58%
ROCE675.50%
Gross Margin-259.66%
Operating Margin-469.23%
Net Margin0.00%
Debt/Equity-1.00
Current Ratio0.11

Annual Financials (USD)

Metric20182019202020212022
Revenue$1.0M$1.0M$1.0M$4.0M$0
Operating Profit$-5.0M$-6.0M$-5.0M$-1.0M$-5.0M
Net Profit$-5.0M$-3.0M$-4.0M$1.0M$-3.0M
EPS$-0.10$-0.06$-0.07$0.01$-0.04
Op Margin-887.6%-438.8%-856.5%-21.0%-12784.5%

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$1.0M$2.0M$1.0M$3.0M$2.0M
Total Liabilities$1.0M$2.0M$3.0M$3.0M$4.0M
Cash$1.0M$1.0M$1.0M$3.0M$2.0M
Borrowings$0$0$1.0M$0$2.0M

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-4.0M$-3.0M$-3.0M$2.0M$-4.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$2.0M$1.0M$0
Net Cash Flow$0$1.0M$-1.0M$2.0M$-1.0M
Free Cash Flow$-4.0M$-3.0M$-3.0M$2.0M$-4.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-0.16
FCF Yield-915.58%
Quick Ratio0.70
Interest Coverage-7.47
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held2.05%
Institutions Held0.00%
Institutions Float Held0.00%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BLFEBioLife Sciences Inc. $0.00 — 0.00 $156683 0.00%
BNYNBanyan Corp. $0.00 — 0.00 $286042 0.00%
EMYSFEasy Technologies Inc. $0.02 +0.00% -0.28 $142220 0.00%
GBLXGB Sciences, Inc. $0.00 — -0.07 $122121 0.00%
GSTCGlobeStar Therapeutics Corporation $0.00 — -0.04 $124111 0.00%

About Bioasis Technologies Inc.

Bioasis Technologies Inc. is a developing biopharmaceutical enterprise dedicated to the discovery and advancement of treatments and diagnostic tools for various neurological conditions. Central to its strategy is the proprietary xB3 platform, an innovative technology designed to overcome the blood-brain barrier (BBB) and effectively deliver therapeutic agents to the central nervous system (CNS). This platform targets a range of CNS disorders, including brain cancers, metabolic illnesses, and neurodegenerative diseases. The company's internal development pipeline includes several promising candidates: xB3-001, aimed at treating brain metastases; xB3-002, focused on glioblastoma; and xB3-007, targeting neurodegenerative diseases. These programs strive to offer both symptomatic relief and disease-modifying interventions. Bioasis also engages in strategic alliances to expand its research and development capabilities. It collaborates with Aposense Limited on the delivery of siRNA therapeutics for CNS disorders, and with Oxyrane UK Ltd. to integrate xB3 with Oxyrane's OxyCAT platform, enhancing enzyme replacement therapy delivery to the brain. Furthermore, a partnership with Janssen Biotech, Inc. focuses on the research, development, and commercialization of novel xB3-based products. A separate collaboration and licensing agreement with Neuramedy Co Ltd. involves the joint development and commercialization of an xB3-optimized version of their antibody, Tomaralimab. Established in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.

Bioasis Technologies Inc. (BIOAF) stock trades at $0.00 with a market capitalization of $7941. The stock is valued at a price-to-earnings (P/E) ratio of -0.12, price-to-book of -0.19, price-to-sales of 0.03. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Bioasis Technologies Inc. generates a return on equity (ROE) of 150.00% — well above the market average, a sign of a high-quality business, return on capital employed of 675.50%, an operating margin of -469.23%, a net profit margin of 0.00%.

Official website: www.bioasis.us

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides